BRAF and neoplasm: Median PFS was comparable between panitumumab and bevacizumab for RAS/BRAF WT and MSS/MSI-L patients but tended to be shorter with panitumumab than bevacizumab in patients with a RAS/BRAF mutation and/or MSI-H, regardless of tumor sidedness (Extended Data Fig. 5).